Search Results

Showing 10 from 24 results

Teva to Present Data Highlighting SD 809 at 20th International Congress of Parkinson s Disease and Movement Disorders

Teva to Present Data from 18 Abstracts in Tardive Dyskinesia and Huntington Disease at the 21st International Congress of Parkinson s Disease and Movement Disorders

Teva Announces Long Term Efficacy and Safety of Deutetrabenazine in European Patients with Debilitating Movement Disorder Tardive Dyskinesia

Facts Figures

  1. USA
  2. About Teva

Teva Advances Pipeline of Movement Disorder Assets with Announcement of Positive Top Line Data from the First Pivotal Study of Investigational Treatment for Patients with Tardive Dyskinesia

A Loved One s Perspective on Living with Tardive Dyskinesia

  1. USA
  2. News & Media
  3. Feature Stories
The emotional impact that a movement disorder like tardive dyskinesia TD can have on mental health can be very heavy

Teva to Present Data Highlighting Company s Pipeline in Neurological Disorders at 68th AAN Annual Meeting

What Teva Is Doing to Help Save the Lives of Thousands of Children with Cancer and Blood Disorders in Africa

  1. USA
  2. News & Media
  3. Feature Stories

Helping Address the Impact of Tardive Dyskinesia

  1. USA
  2. News & Media
  3. Feature Stories
Dr Richard Jackson Assistant Clinical Adjunct Professor University of Michigan School of Medicine Department of Psychiatry discusses the challenges both patients and doctors face when it comes to discussing the impact that tardive dyskinesia can have on patients lives which led to the creation of the IMPACT TD scale

Teva Phase IV UNITE Study Shows AJOVY fremanezumab Reduced Migraine Attacks and Depression Symptoms in Migraine Sufferers with Major Depressive Disorder